Novavax, Inc (NASDAQ: NVAX) on Friday, plunged -2.71% from the previous trading day, before settling in for the closing price of $9.61. Within the past 52 weeks, NVAX’s price has moved between $3.53 and $23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 513.29% over the last five years. The company achieved an average annual earnings per share of 81.38%. With a float of $153.03 million, this company’s outstanding shares have now reached $160.09 million.
The firm has a total of 1543 workers. Let’s measure their productivity. In terms of profitability, gross margin is 59.57%, operating margin of -34.74%, and the pretax margin is -35.11%.
Novavax, Inc (NVAX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Novavax, Inc is 4.42%, while institutional ownership is 53.34%. The most recent insider transaction that took place on Sep 18 ’24, was worth 95,331. Before that another transaction happened on Jun 21 ’24, when Company’s Director sold 7,500 for $14.09, making the entire transaction worth $105,675. This insider now owns 61,760 shares in total.
Novavax, Inc (NVAX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 81.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to 11.55% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Novavax, Inc (NVAX) is currently performing well based on its current performance indicators. A quick ratio of 1.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.77, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach 0.04 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Analysing the last 5-days average volume posted by the [Novavax, Inc, NVAX], we can find that recorded value of 4.33 million was lower than the volume posted last year of 9.92 million. As of the previous 9 days, the stock’s Stochastic %D was 12.82%. Additionally, its Average True Range was 0.77.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 5.37%, which indicates a significant increase from 1.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.21% in the past 14 days, which was lower than the 97.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.91, while its 200-day Moving Average is $9.80. Now, the first resistance to watch is $9.72. This is followed by the second major resistance level at $10.08. The third major resistance level sits at $10.30. If the price goes on to break the first support level at $9.14, it is likely to go to the next support level at $8.92. Should the price break the second support level, the third support level stands at $8.56.
Novavax, Inc (NASDAQ: NVAX) Key Stats
Market capitalization of the company is 1.46 billion based on 160,094K outstanding shares. Right now, sales total 983,710 K and income totals -545,060 K. The company made 415,480 K in profit during its latest quarter, and 162,380 K in sales during its previous quarter.
